# 1 Title: Provider-led community Antiretroviral Therapy distribution in Malawi: Retrospective

# 2 cohort study of retention, viral load suppression, and costs.

- 3 John Songo<sup>1</sup>, Hannah Whitehead<sup>2</sup>, Brooke Nichols<sup>3</sup>, Amos Makwaya<sup>1</sup>, Joseph Njala<sup>1</sup>, Sam
- 4 Phiri<sup>1,4</sup>, Risa M. Hoffman<sup>2</sup>, Kathryn Dovel<sup>2</sup> Khumbo Phiri<sup>1</sup>, Joep J. van Oosterhout<sup>1,2</sup>

# 5 Affiliations

- 6 <sup>1</sup>Partners in Hope, Lilongwe, Malawi;
- 7 <sup>2</sup>Department of Medicine, Division of Infectious Diseases, David Geffen School of Medicine,
- 8 UCLA, Los Angeles, California, USA;
- 9 <sup>3</sup>FIND, Geneva, Switzerland.
- 10 <sup>4</sup>Department of Public Health and Family Medicine, Kamuzu University of Health Sciences,
- 11 Lilongwe, Malawi
- 12
- 13 Corresponding Author: John Songo
- 14 Email: pemphosongo@gmail.com
- 15

### 16 Abstract

Background: Outcomes of community antiretroviral therapy (ART) distribution (CAD), in which
provider-led ART teams deliver integrated HIV services at health posts in communities, have
been mixed in sub-Saharan African countries. CAD outcomes and costs relative to facility-based
care have not been reported from Malawi.
Methods: We performed a retrospective cohort study in two Malawian districts (Lilongwe and
Chikwawa districts), comparing CAD with facility-based ART care. We selected an equal number

of clients in CAD and facility-based care who were aged >13 years, had an undetectable viral

load (VL) result in the last year and were stable on first-line ART for ≥1 year. We compared

25 retention in care (alive and no period of ≥60 days without ART) using Kaplan-Meier survival

26 analysis and Cox regression and maintenance of VL suppression (<1,000 copies/mL) during

27 follow-up using logistic regression. We also compared costs (in US\$) from the health system

and client perspectives for the two models of care. Data were collected in October and

29 November 2020.

30 **Results:** 700 ART clients (350 CAD, 350 facility-based) were included. The median age was 43

31 years (IQR 36-51), median duration on ART was 7 years (IQR 4-9), and 75% were female.

32 Retention in care did not differ significantly between clients in CAD (89.4% retained) and

33 facility-based care (89.3%), p=0.95. No significant difference in maintenance of VL suppression

34 were observed between CAD and facility-based care (aOR: 1.24, 95% CI: 0.47-3.20, p=0.70).

35 CAD resulted in slightly higher health system costs than facility-based care: \$118/year vs.

36 \$108/year per person accessing care; and \$133/year vs. \$122/year per person retained in care.

- 37 CAD decreased individual client costs compared to facility-based care: \$3.20/year vs.
- 38 \$11.40/year per person accessing care; and \$3.60/year vs. \$12.90/year per person retained in
- 39 care.
- 40 Conclusion: Clients in provider-led CAD care in Malawi had very good retention in care and VL
- 41 suppression outcomes, similar to clients receiving facility-based care. While health system costs
- 42 were somewhat higher with CAD, costs for clients were reduced substantially. More research is
- 43 needed to understand the impact of other differentiated service delivery models on costs for
- 44 the health system and clients.

## 45 Introduction

46	Antiretroviral therapy (ART) coverage has expanded greatly in sub-Saharan Africa and Malawi
47	over the past 20 years (1). The sharply risen number of ART clients has resulted in health
48	system challenges such as long waiting times, insufficient staffing and limited space (2).
49	Together with the need for more client-centered and tailored care, such challenges have
50	inspired innovative ways of delivering care to clients, broadly referred to as differentiated
51	service delivery (DSD) models (3). Provider-led and community-led Community ART Distribution
52	(CAD) DSD models have been implemented in Sub-Saharan Africa since 2010 (4). In provider-
53	led CAD, a team of health care workers (HCWs) travels to small, community-based health posts
54	to provide comprehensive HIV services, including dispensing ART refills, on scheduled days. In
55	community-led CAD, ART clients form groups and one community member collects ART refills at
56	the facility for the whole group (5). Compared to facility-based services, CAD brings HIV care
57	closer to people's homes, thereby reducing travel time, travel costs and opportunity costs,
58	which may improve adherence and facilitate retention in care (3,6).
59	Despite widespread implementation of CAD across sub-Saharan Africa, evidence regarding its
60	effectiveness and cost-effectiveness in improving retention and viral load (VL) suppression is
61	limited, outcomes have varied and none have been reported from Malawi. An early systematic
62	review of studies from sub-Saharan Africa suggested that retention in care is higher in provider-
63	and community-led CAD than in standard facility-based care (6), but two later randomized trials
64	in Zimbabwe and Lesotho found that retention in care and VL suppression did not differ
65	significantly between health facility-based care, community-led CAD, and provider-led CAD

- 66 (7,8). Compared to standard facility-based care, CAD models had higher health system cost per
- 67 client retained in care at 12 months in Zambia (9).
- 68 Comparing retrospective cohort data from clients receiving provider-led CAD and clients
- 69 receiving facility-based care, we sought to evaluate the impact of provider-led CAD services on
- 70 retention and VL suppression in Malawi. We also assess differences in cost between provider-
- 71 led CAD services and facility-based care from a health systems and individual client perspective.

### 72 Methods

### 73 Study setting

74 Partners In Hope (PIH) is a Malawian non-governmental organization that provides PEPFAR-

75 funded support for HIV services in Malawi's National HIV program. PIH implements a provider-

76 led CAD model for stable (suppressed VL <1,000 copies/mL and on first-line ART) individuals at

4 health facilities in Lilongwe (urban setting, n=2) and Chikwawa (rural setting, n=2) districts,

78 with a total of 20 CAD outreach sites. Provider-led CAD follows a hub-and-spoke model where a

team of HCWs travels once a month from the hub (a large health facility) to a spoke (a village-

80 based health post). The team is generally led by a nurse or occasionally a clinical officer, and

81 includes an HIV diagnostic assistant (HDA), Treatment Supporter, counsellor and driver. Once a

82 quarter, a data clerk joins the team. Services provided at CAD spokes include ART refills, VL

83 sample collection, HIV testing services, family planning, screening for non-communicable

84 diseases, referral to community services and adherence assessment and counselling.

### 85 Study design and data collection

We conducted a retrospective cohort study making use of routinely collected data from 86 87 standard medical records of 700 ART clients receiving ART care through CAD or health facilitybased services. Data were collected in October-November 2020, from two 'hub' health facilities 88 89 in Chikwawa and two in Lilongwe, and 20 associated CAD 'spoke' sites. We selected all the 90 clients registered in CAD between January 2019 (when CAD implementation began) and June 91 2019, and collected data from their first visit through August 2020 to allow for 14 months of 92 observation time. Clients can choose to be enrolled into provider-led CAD if they meet 93 programmatic criteria: being stable on first-line ART for more than 12 months, registered at a 94 hub site, ready to disclose HIV status to other members of the CAD spoke, undetectable result 95 of the last VL test (within 12 months), and age 13 years or older. We then compiled a list of 96 individuals receiving standard care at the four hub facilities ("controls"). The inclusion criteria 97 for controls were the same as for CAD enrolment mentioned above, except for the disclosure criterion. The number of controls included for each hub was equal to the number of CAD clients 98 99 enrolled from that hub facility's CAD spokes. We selected hub controls chronologically, starting 100 with those who had visited the facility in January 2019, and proceeding until the required 101 number of clients was reached.

We extracted data on all recorded visits for 14 months after study entry from clients' individual
ART master-cards. A 14-month period was used to be able to capture full 1-year outcomes,
including defaulting, as defined below. Collected data included: demographic characteristics,
ART initiation date, dates of all CAD/facility visits, results of annual routine VL tests, and
standardized ART outcomes (default, transfer out, stopped ART, death). All data were collected

on Android tablets using the SurveyCTO electronic data collection platform. Additional VL test
 results were extracted from the National Laboratory Information Systems Management (LIMS)
 Database, if missing on ART master-cards. No personal identifiers were collected from the data
 sources and therefore all data were anonymized. Ethical approval for the study was obtained
 from the National Health Sciences Research Committee in Malawi (#1099).

#### 112 Key study definitions

113 *Adverse outcome:* recorded to have died, defaulted or stopped ART during follow-up. For 114 individuals with multiple adverse outcomes recorded, the earliest outcome was used for all 115 analyses. For example, if a client had defaulted, then returned to care, and subsequently died, 116 they were classified as having defaulted.

*Defaulted*: per national guidelines, defaulting from care was defined as being overdue for an ART
 refill appointment and estimated to have run out of ARVs for 2 months or longer, based on the

119 quantity of ARVs dispensed at the last visit (10).

Viral load outcomes: VL results were categorized according to national HIV guidelines: high VL (≥1000 copies/ml); low level viremia (200-999 copies/mL); or suppressed VL (undetectable-199 copies/mL). For logistic regression analyses, we applied a commonly-used binary VL outcome: 
122 copies/mL and ≥1000 copies/mL (11). VL results were only included from samples taken at least 6 months and no more than 18 months after enrollment into CAD or from the first visit in the study period for controls. We extended the period for VL results from 14 to 18 months due to the infrequency of VL testing during the study period.

# 127 Statistical analysis

128	Descriptive statistics were generated for client characteristics and outcomes. We compared
129	viral load outcomes between the two models of care using chi-square tests and logistic
130	regression. We used Kaplan-Meier survival analysis methods to compare retention in care at
131	CAD spokes versus hub facilities over the 14 months of follow-up. Each client started
132	contributing person-time to the analysis from the day that they were in enrolled into CAD or
133	the earliest day that they visited the hub facility between January 2019 and June 2019. Follow-
134	up time of clients who transferred to another health facility and of those who remained in care
135	at the end of the follow-up period was censored on their last recorded visit day within the 14
136	months follow up period. We used Cox regression to produce crude and adjusted hazard ratios
137	(aHR) of experiencing an adverse outcome, adjusting for sex, age and district.
138	Univariate analysis of the association between key outcome variables and the intervention
139	were stratified by gender to take into account significant gender differences across the HIV care
140	cascade in Malawi (12).
141	We assessed the extent of missing data in the sample by key outcome variables and covariates
142	(retention, VL suppression, sex, age and district). Only VL suppression had missing data (21%)
143	but the missing data did not vary by arm of intervention (CAD/hub) (p= 0.09). All observations
144	with missing data on VL suppression were excluded from the analysis on VL suppression.

146 Cost analysis

145

147 We calculated the cost per person retained for both facility-based care and CAD care from a148 health systems and individual client perspective.

All analyses were conducted with Stata v17 (Stata Corp., Texas, USA).

Table 1 describes the unit costs collected locally or derived from the literature for both the cost to the health system and the cost to the client. For health systems cost per CAD spoke clinic day, we include all additional activities required to successfully implement a CAD visit, including use of a vehicle to and from the CAD (average of 32km round-trip per CAD visit), and the cost of a day of the full clinical team's services. The total costs were divided by the number of visiting clients to each CAD included in the study to determine the cost per individual client CAD visit.

155 **Table 1** Unit costs included in analysis

Variable	Unit cost (USD) 2022	Sources
Provider costs		
Hub clinic visit	\$2.90	(13)
CAD spoke visit	\$5.95	Program implementation data (2022)
ART day (first-line)	\$0.21	(13)
Viral load	\$14.2	(13)
Cost to client		
Wage lost for hub facility visit*	\$2.50	In-country information
Wages lost for CAD spoke visit**	\$0.625	In-country information

156 \*1 day of minimum wage lost; \*\*0.25 day of minimum wage lost

### 157 Results

### 158 Sample characteristics at enrolment

- 159 We collected data on 700 ART clients, 350 from provider-led CAD and 350 from facility care
- 160 (Table 2). Approximately 75% of both CAD and hub clients were female. Clients at CAD spokes
- 161 were older (45.3 vs. 42.2 years) and had been on ART for longer (7.2 vs. 6.4 years).

	Overall		CAD spok	es	Hub facilities		
Variable							
	n	%	n	%	n	%	
Total	700	100	350	50.0	350	50.0	
Age							
Median, years (IQR)	43.8 (36.5	5- 51.4)	45.3 (38.3	3- 54.1)	42.2 (34.6	5- 49.4)	
13-24 years	27	3.9	10	2.8	17	4.9	
25-34 years	111	15.9	38	10.8	73	20.9	
35-44 years	246	35.1	123	35.1	123	35.1	
45-54 years	182	26.0	97	27.7	85	24.2	
55+ years	134	19.1	82	23.4	52	14.9	
Sex							
Male	178	25.4	87	24.9	91	26.0	
Female	522	74.6	263	75.1	259	74.0	
Duration on ART							
Median (IQR)	6.8 (4.1- 9	9.7)	7.2 (4.2-	9.9)	6.4 (3.9-	9.3)	
<4year	171	24.4	81	23.1	90	25.7	
4-8years	251	35.9	119	34.0	132	37.7	
>8years	278	39.7	150	42.9	128	36.6	
District							
Lilongwe	228	32.6	114	32.6	114	32.6	
Chikwawa	472	67.4	236	67.4	236	67.4	

# 162 **Table 2.** Characteristics of clients at enrollment in CAD spokes and at hub health facilities (controls)

### 164 *Client outcomes*

- 165 Descriptive outcomes at 14 months of follow up
- 166 At the end of the 14-months of follow-up, approximately 1% of participants had died, 10% had
- defaulted, and 5% had transferred to another health facility. Differences in standard client
- 168 outcomes between CAD and facility-based care were minimal and not statistically significant,
- 169 either overall or when stratified by sex (Table 3).

### 170 Table 3 Client outcomes at 14 Months

Overall						Males					Females				
	C/	CAD Hub			C	AD	Hub			CAD		Hub			
Outcome	n	%	n	%	p-value	n	%	n	%	p-value	n	%	n	%	p-value
Died	4	1.1	3	0.9		3	3.4	2	2.2		1	0.4	1	0.4	
Stopped ART	0	0.0	0	0.0		0	0.0	0	0.0		0	0.0	0	0.0	
Defaulted	35	10.0	34	9.7	0.619	13	14.9	11	12.1	0.832	22	8.4	23	8.9	0.387
Transferred Out	12	3.4	19	5.4		4	4.6	3	3.3		8	3.0	16	6.2	
Alive on ART	299	85.4	294	84.0		67	77.0	75	82.4		232	88.2	219	84.6	
Total	350	100	350	100		87	100	91	100		263	100	259	100	

171

# 172 Kaplan-Meier survival estimates of retention in care at 14 months of follow up.

173 The average follow-up time was 11.6 months for clients at CAD spokes and 11.1 months at hub

- 174 facilities. The cumulative probability of retention in care over the follow-up period was not
- significantly different between clients in provider-led CAD and facility-based HIV care (88.4% vs.

176	88.3%; p-value 0.95) (Figure 1). Sex was the only covariate with a statistically significant impact
177	on retention in the total study population (males 80.4% vs. females 90.8%; p =0.005) (Figure 2).
178	
179	Figure 1: Kaplan-Meier survival estimates of retention over 14 months of follow up by model of
180	care
181	Figure 2: Kaplan-Meier survival estimates of retention over 14 months of follow up by gender
182	
183	Controlling for sex, age, and district of residence, the risk of experiencing an adverse outcome
184	was similar for clients in provider-led CAD and facility-based care (aHR: 1.05, 95%CI: 0.66-1.66,
185	P-value: 0.80)
186	Viral load outcomes
187	VL test results were available for 553 clients, representing 79% of the overall sample (82% of
188	CAD clients; 76% of hub clients; p= 0.09). In univariable analyses, standard VL outcomes were
189	not significantly different between CAD and health facility-based care, whether overall or
190	stratified by sex (Table 4). After adjusting for sex, duration on ART, age, and district of
191	residence, there was no significant difference in prevalence of VL <1,000 copies/ml between
192	clients in CAD (97%) and in hub care (96%): aOR 1.24, 95% CI 0.47-3.26, p-value 0.66.
193	
194	

### 196 Table 4 Viral load suppression

	Overall					Males				Females					
	CA	D	Н	ub		C.	AD	F	lub		c	AD	Н	ub	
VL	n	%	n	%	p-value	n	%	n	%	p-value	n	%	n	%	p-value
≥1000 copies/ml	8	2.8	10	3.7		2	3.0	2	3.1		6	2.7	8	3.9	
200-999 copies/mL	57	20.0	40	14.9	0.260	14	21.2	7	10.8	0.264	43	19.6	33	16.3	0.552
undetectable-199 copies/mL	220	77.2	218	81.3		50	75.8	56	86.2		170	77.6	162	79.8	
Total	285	100	268	100		66	100	65	100		219	100	203	100	

197

## 198 *Costs*

199 Table 5 describes the resources used per client for both CAD-based and facility-based care.

200 Differences in resource use, considering the standard deviations, were small between the

201 models of care.

202 Table 5 Resource utilization of CAD-based care and facility-based care in Malawi (average and standard

203 deviation)

Variable	CAD-based care	Facility-based care
Number of clinic visits	0	4.6 (SD 1.4)
Number of CAD visits	5.1 (SD 1.5)	0
Number of ART days	351 (SD 92)	383 (SD 91)
Number of viral load tests	0.9 (SD 0.7)	1.0 (SD 0.6)

204

205 The total costs per person receiving care and the costs per person retained by model of care,

206 from a health systems and individual client perspective, are described in Table 6. Health system

207 cost estimates for provider-led CAD were \$118 per person receiving care per year and \$108 per

208 person per year in facility-based care. Cost for individual clients was lower in provider-led CAD

- 209 (\$3.17 per person per year) than facility-based care (\$11.44 per person per year). In a second
- analysis limited to those retained in care, the gap in health systems costs between the two
- 211 models of care was the same (\$10 lower in provider-led CAD), while differences in costs for
- clients widened slightly (from \$8.27 reduced cost per client to \$9.30 reduced cost for client
- 213 retained in provider-led CAD).
- Table 2. Cost per person in care and cost per person retained comparing facility- and provider-led CAD-
- 215 (based on 2022 USD)

Variable	CAD	Facility-based care
Health system cost		
Cost per client	\$118 (SD \$29)	\$108 (SD \$24)
Cost per client retained	133	122
Client cost		
Cost per client	\$3.17 (SD \$0.96)	\$11.44 (SD \$3.53)
Cost per client retained	3.58	12.88

216

#### 217 Discussion

- 218 In a retrospective assessment of two models of HIV care in Malawi, we found that retention in
- 219 care and viral suppression outcomes were similar in provider-led CAD as compared to facility-
- based care. While health system cost per person provided care and per person retained in care
- were 9% higher in provider-led CAD, cost for 12-months of HIV care incurred by clients was 72%
- 222 lower in CAD than in facility-based care.
- 223 Prior studies of CAD in sub-Saharan Africa had mixed findings. In two similar cluster randomized
- trials, one in Lesotho and one in Zimbabwe, no significant differences in retention in care and
- 225 VL suppression were observed between facility-based 3-monthly ART (control), 3-monthly
- community ART groups, and 6-monthly provided-led CAD (7,8). In contrast, in a retrospective

227	cohort study from Mozambique, retention in care was significantly higher among clients in
228	community-led CAD (at 99.1% at 12 months) than in facility-based care (89.5%, p<0.0001) (14).
229	In the same setting, another retrospective cohort study found that individuals in facility-based
230	care were more than twice as likely to be lost to follow up (HR 2.356; $p = 0.04$ ) than matched
231	participants in community-led CAD (5). Differences in the organization of CAD services,
232	variations in the local setting (including rural vs. urban) and the degree of donor support may
233	explain these variations in ART outcomes. It has been suggested that in community-led CADs,
234	clients acquire ownership of their ART care, as group representatives take turns to collect ART
235	at the facility for the whole group and members actively trace group members who miss a
236	group ART distribution session (14). Such activities may increase group members' ability to self-
237	manage their own care (15) and lead to better retention and VL suppression. To date, CADs are
238	largely only available to stable ART clients and this presents potential missed opportunities to
239	engage non-stable clients in CAD.
240	From a health systems perspective, provider-led CAD is slightly more expensive than facility-
241	based care. The difference was relatively small (9% higher, or approximately \$10 more per
242	person receiving care per year). Additional costs are due to HCWs traveling to CAD locations,
243	but the vast majority of ART costs are generated by medication and VL testing, which do not
244	vary by provider-led CAD or facility-based care. However, we found that provider-led CAD

substantially reduced costs for clients by nearly three-quarters, mainly due to lower

246 opportunity costs as clients need less travel time to access ART services. Health system costs of

247 provider-led CAD can be reduced by decreasing the frequency of the team's travels to

248 distribution sites, in combination with expansion of multi-month dispensing. This may also

further reduce clients' costs and could benefit retention and viral suppression outcomes (16).
Our results are consistent with findings from the only other study from the region that assessed
costs and outcomes across community-based ART models. In this study from Zambia, costs for
CAD models ranged from an annual \$116/person to \$199/person compared with \$100/person
for facility-care (9).

A limitation of our cost analysis is that we did not incorporate travel costs for clients (cost of

transportation to/from facility-based care) as many clients walk, use their own bicycle or make

256 informal arrangements that are not directly tied to financial cost. It is therefore highly likely

257 that we underestimated the difference in clients' costs and provider-led CAD may have a

258 greater financial benefit to clients than reported here. This is supported by a qualitative study

259 on client and nurse perspectives of provider-led community-based models of HIV care in

260 Malawi, where clients reported that CAD services resulted in savings on transportation costs

and the time it took them to travel to a health facility (17).

As is common with observational studies, our results may be prone to bias as clients enrolled in CAD are selected based on specific characteristics, such as being clinically stable, which cannot be completely adjusted for in statistical analyses. However, great effort was put into ensuring that the eligibility criteria used for enrolment into CAD is adhered to during selection of controls through a strict study enrolment protocol that was double checked at data collection and at analysis.

### 268 Conclusions

Provider-led CAD services in Malawi had excellent one-year retention and VL suppression
results that were similar to facility-based care. CAD was associated with a small increase in the

- 271 financial costs to the health system but substantial savings for clients, which may benefit longer
- term engagement in care and ART outcomes. More study is need to determine cost-
- 273 effectiveness of different DSD models in sub-Saharan Africa.

## 274 Acknowledgements.

- 275 We are grateful for funding by PEPFAR through USAID that allowed Partners in Hope to
- implement the provider-led CAD program and to collect the data for this analysis. We also
- thank the support of the participating health facilities and their management teams.

# 278 References

- Geneva: Joint United Nations Programme on HIV/AIDS. UNAIDS data 2021 [Internet].
   2021. Available from:
- https://www.unaids.org/sites/default/files/media\_asset/JC3032\_AIDS\_Data\_book\_2021
   En.pdf
- Kalua T, Tippett Barr BA, van Oosterhout JJ, Mbori-Ngacha D, Schouten EJ, Gupta S, et al.
   Lessons Learned From Option B+ in the Evolution Toward "Test and Start" From Malawi,
   Cameroon, and the United Republic of Tanzania. JAIDS J Acquir Immune Defic Syndr
- 286 [Internet]. 2017 May 1;75(1):S43–50. Available from:
- 287 http://insights.ovid.com/crossref?an=00126334-201705011-
- 288 00007%0Ahttp://www.ncbi.nlm.nih.gov/pubmed/28398996
- Davis N, Kanagat N, Sharer M, Eagan S, Pearson J, Amanyeiwe UU. Review of
   differentiated approaches to antiretroviral therapy distribution. AIDS Care Psychol
   Socio-Medical Asp AIDS/HIV [Internet]. 2018;30(8):1010–6. Available from:
   https://doi.org/10.1080/09540121.2018.1441970
- Vogt F, Kalenga L, Lukela J, Salumu F, Diallo I, Nico E, et al. Brief Report: Decentralizing
   ART Supply for Stable HIV Patients to Community-Based Distribution Centers: Program
   Outcomes From an Urban Context in Kinshasa, DRC. JAIDS J Acquir Immune Defic Syndr
   [Internet]. 2017 Mar 1;74(3):326–31. Available from:
   https://journals.lww.com/00126334-201703010-00014
- Jobarteh K, Shiraishi RW, Malimane I, Gudo PS, Decroo T, Auld AF, et al. Community ART
   support groups in Mozambique: The potential of patients as partners in care. PLoS One.
   2016;11(12):1–14.
- Decroo T, Rasschaert F, Telfer B, Remartinez D, Laga M, Ford N. Community-based antiretroviral therapy programs can overcome barriers to retention of patients and decongest health services in sub-Saharan Africa: a systematic review. Int Health [Internet]. 2013 Sep 1;5(3):169–79. Available from:
- 305 https://academic.oup.com/inthealth/article-lookup/doi/10.1093/inthealth/iht016
- Fatti G, Ngorima-Mabhena N, Mothibi E, Muzenda T, Choto R, Kasu T, et al. Outcomes of
   Three- Versus Six-Monthly Dispensing of Antiretroviral Treatment (ART) for Stable HIV
   Patients in Community ART Refill Groups: A Cluster-Randomized Trial in Zimbabwe. J
   Acquir Immune Defic Syndr. 2020;84(2):162–72.
- Tukei BB, Fatti G, Tiam A, Ngorima-Mabhena N, Tukei VJ, Tshabalala I, et al. Twelve Month Outcomes of Community-Based Differentiated Models of Multimonth Dispensing
   of ART Among Stable HIV-Infected Adults in Lesotho: A Cluster-Randomized
   Noninferiority Trial. J Acquir Immune Defic Syndr. 2020;85(3):280–91.
- Nichols BE, Cele R, Jamieson L, Long LC, Siwale Z, Banda P, et al. Community-based
   delivery of HIV treatment in Zambia: costs and outcomes. AIDS. 2021;35(2):299–306.

316 317	10.	Malawi Ministry of Health. Clinical Management of HIV in Children and Adults. Lilongwe; 2018.
318 319 320	11.	World Health Organization. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach. Geneva; 2021.
321 322 323	12.	United Nations Programme on HIV/aids. UNAIDS. UNAIDS data 2021 [Internet]. 2021. Available from: https://www.unaids.org/en/resources/documents/2021/2021_unaids_data
324 325 326 327	13.	Nichols BE, Offorjebe OA, Cele R, Shaba F, Balakasi K, Chivwara M, et al. Economic evaluation of facility-based HIV self-testing among adult outpatients in Malawi. J Int AIDS Soc [Internet]. 2020 Sep 9;23(9):e25612. Available from: https://onlinelibrary.wiley.com/doi/10.1002/jia2.25612
328 329 330	14.	Decroo T, Telfer B, Dores C Das, White RA, Santos N Dos, Mkwamba A, et al. Effect of Community ART Groups on retention-in-care among patients on ART in Tete Province, Mozambique: A cohort study. BMJ Open. 2017;7(8):1–9.
331 332 333	15.	Dudhia R, Kagee A. Experiences of participating in an antiretroviral treatment adherence club. Psychol Health Med [Internet]. 2015 May 19;20(4):488–94. Available from: http://www.tandfonline.com/doi/full/10.1080/13548506.2014.953962
334 335 336	16.	Rasschaert F, Telfer B, Lessitala F, Decroo T, Remartinez D, Biot M, et al. A qualitative assessment of a community antiretroviral therapy group model in Tete, Mozambique. PLoS One. 2014;9(3):1–11.
337 338 339	17.	Sande O, Burtscher D, Kathumba D, Tweya H, Phiri S, Gugsa S. Patient and nurse perspectives of a nurse-led community-based model of HIV care delivery in Malawi: A qualitative study. BMC Public Health. 2020;20(1):1–8.



Figure 1



Figure 2